Efficacy of Biomarkers and CEUS Versus CTA in AAA Follow-up Post-EVAR

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with an abdominal aortic aneurysm (a bulge in the main belly artery) who are going to have EVAR, a repair done from inside the artery.

Életkor

18 Years and older

Nem

All

A betegség stádiuma

Abdominal aortic aneurysm that has not burst, under follow-up, planned for EVAR repair.

Korábbi kezelés

People must be going to be treated with EVAR.

A részvétel fő kizáró okai

• Inflammatory abdominal aortic aneurysm
• Ruptured (burst) aneurysm
• No signed consent for CTA, CEUS and biomarker tests

A regiszter feltételei, szó szerint

Mit akar kideríteni a vizsgálat

This prospective observational study evaluates the efficacy of contrast-enhanced ultrasound and biomarker determination in the follow-up of patients with abdominal aortic aneurysm (AAA) treated with Endovascular Aneurysm Repair (EVAR). Currently, computed tomography angiography (CTA) is the standard for follow-up, although it has disadvantages such as radiation exposure and the use of iodinated contrasts. Contrast-enhanced ultrasound (CEUS), free of radiation and nephrotoxicity, and biomarkers could reduce the need for CTA minimizing the associated risks. Biomarkers will be measured before and after EVAR and CEUS will be performed at various time points and compared with CTA results to validate concordance and effectiveness in detecting endoleaks and aneurysm remodeling. The objectives include determining the efficacy of these combined methods and establishing a follow-up protocol that reduces exposure to radiation and iodinated contrast agents.

A vizsgálat csoportja

• Study cohort

  Inclusion Criteria: * patients with AAA under follow-up who are going to be treated with EVAR. * signed informed consent to perform CTA, CEUS and for the determination of biomarkers. Exclusion Criteria: * patients with inflammatory abdominal aortic aneurysms or ruptured aneurysm.

  Kezelés: CTA